MediciNova, Inc.
MediciNova, Inc. (MNOV) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mnov · stock forecast · 4 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.30
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.27 | ↓ 2.11% |
1-day model range: $1.27–$1.28. Peak: $1.28 (-2.11%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · MNOV · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-04 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-01-30 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-12-18 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-12-08 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-04 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-10-31 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-09-22 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-08-27 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-07-24 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-06-16 | B. Riley Securities | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on MediciNova, Inc. (MNOV) stock. Of the recent 17 rating actions, 0 were upgrades and 0 were downgrades. 4 analysts currently cover MNOV.
Analyst Recommendation Trends
MNOV analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 99.3% YoY
Revenue Next Year
$1M
↑ 170.6% YoY
EPS This Year
$-0.26
EPS Next Year
$-0.38
↑ 44.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast MNOV EPS of $-0.26 for the current fiscal year, based on estimates from 2 analysts. The MNOV revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MNOV stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MNOV price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The MNOV short-term stock prediction for tomorrow is $1.27 (-2.11%). The MNOV stock price prediction for 2027 estimates an average of $1. The MNOV stock prediction for 2030 projects a range of $0–$0.
MediciNova, Inc. trades on NASDAQ under the ticker MNOV. The MNOV stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
MNOV forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month MNOV price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.30.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.